Skip to content

Svennilson Peter

Follow

13F filer, CIK 1606074, SAN FRANCISCO, CA

Svennilson Peter reported $349,925,000 across 4 holdings for the quarter ended 2019-06-30, in a 13F-HR filed 2019-08-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001600420-19-000007

Period
2019-06-30
Reported value
$350M
Holdings
4
Top 10 weight
100%
New
1
Sold out
1

Stakes and trades reported after 2019-06-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • SRZN SURROZEN INC: 13D/A 3,813,501 shares, 18.2% of the class, 13D/A filed 2026-11-18, 0001193125-26-467393Timeline
    Accepted , ingested
  • TNYA TENAYA THERAPEUTICS INC: 13D/A 49,313,559 shares, 21.6% of the class, 13D/A filed 2026-11-16, 0001193125-26-463722Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
NGM BIOPHARMACEUTICALS INCnew+15,694,091$230M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
IMMUNE DESIGN CORP.exited-6,642,942-$38.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2019

Share positions as resolved from 13F-HR 0001600420-19-000007, largest first. % of portfolio is the value over $349,925,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: not reported; 2019Q1: not reported; 2019Q2: 15,694,091 shares 15,694,091$230M65.66%new
CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICALQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 4,677,938 shares; 2019Q1: 4,677,939 shares; 2019Q2: 4,677,939 shares 4,677,939$57.4M16.42%0
GRITSTONE BIO INCGRITSTONE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 3,102,934 shares; 2019Q1: 3,102,934 shares; 2019Q2: 3,102,934 shares 3,102,934$34.6M9.88%0
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2017Q3: restricted; 2017Q4: restricted; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 3,540,850 shares; 2019Q1: 3,540,850 shares; 2019Q2: 3,540,850 shares 3,540,850$28.1M8.04%0Timeline

Sold out in Q2 2019

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
IMMUNE DESIGN CORP.IMMUNE DESIGN CORP.6,642,942$38.9Mshares

How Q2 2019 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001600420-19-000007 base2019-08-14acceptance time not in the bulk data set